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bS Supporting Information
Disrupted in schizophrenia 1 (DISC1), a protein originallyidentiﬁed from a gene directly disrupted by a balanced trans-
location in a large Scottish family with a high loading of major
mental illness,1,2 is now established by considerable genetic evi-
dence as a risk factor for a wide array of psychiatric illnesses
including schizophrenia, bipolar disorder, major depression, and
potentially autism spectrum disorders (reviewed in refs 3 and 4).
Recently, the term “DISCopathies” was coined to classify brain
disorders related to dysfunctional DISC1 protein as a single disease
entity.5 DISC1 is present at the intersection of several neurode-
velopmental pathways, one or more of which aﬀect major mental
illness pathology. It acts as a scaﬀold, binding a number of other
proteins several of which have been shown to be independent
risk factors for major mental illness (reviewed in ref 4).
The DISC1 protein interaction network therefore makes an
attractive target for future therapeutic intervention,6 and already
some evidence shows DISC1 to be aﬀected by known therapeutic
drugs, with the atypical antipsychotics olanzapine and risperidone
altering DISC1 transcript levels in the mouse brain.7 Addition-
ally, depression and schizophrenia-related phenotypes seen in
two mouse models of DISC1 mutation are partially restored by
the antidepressant bupropion or the antipsychotics haloperidol
and clozapine, respectively.8 Furthermore, these mental-illness-
related phenotypes are also treated in part by inhibitors of
glycogen synthase kinase 3β (GSK3β),9,10 a DISC1 interacting
protein whose other inhibitors include the potent mood stabi-
lizer, lithium.11 While it therefore appears that DISC1 acts on
known therapeutic pathways, it is perhaps even more exciting
that variation in DISC1 may be associated with forms of schizo-
phrenia resilient to treatment.12 While these results have yet to be
successfully replicated,13 they imply that DISC1 may provide a
target for the development of treatments for some of the suﬀerers
of major mental illness for whom current pharmaceuticals are of
limited or no use.
The DISC1 protein itself, however, at present, represents a
diﬃcult drug target due to lack of a known or anticipated
enzymatic activity and the absence of a solved crystal structure.
A recent report demonstrated that DISC1 function can be
dynamically regulated via phosphorylation,14 highlighting the
possibility for the development of pharmacotherapies directly
targeting DISC1. Any DISC1-based therapeutic molecule would
most likely have to either modulate interaction of DISC1 with
one of its many protein binding partners, the design of which
would be greatly facilitated by a detailed understanding of the
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ABSTRACT: Disrupted in schizophrenia 1 (DISC1) is well
established as a genetic risk factor across a spectrum of
psychiatric disorders, a role supported by a growing body of
biological studies, making the DISC1 protein interaction net-
work an attractive therapeutic target. By contrast, there is a
relative deﬁcit of structural information to relate to the myriad
biological functions of DISC1. Here, we critically appraise the
available bioinformatics and biochemical analyses on DISC1
and key interacting proteins, and integrate this with the genetic
and biological data. We review, analyze, and make predictions
regarding the secondary structure and propensity for disordered
regions within DISC1, its protein-interaction domains, subcellular localization motifs, and the structural and functional implications
of common and ultrarare DISC1 variants associated with major mental illness. We discuss signaling pathways of high
pharmacological potential wherein DISC1 participates, including those involving phosphodiesterase 4 (PDE4) and glycogen
synthase kinase 3 (GSK3). These predictions and priority areas can inform future research in the translational and potentially guide
the therapeutic processes.
KEYWORDS: DISC1, schizophrenia, structure, bioinformatics, GSK3β, therapeutic potential
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three-dimensional (3-D) structure of DISC1 to aid rational drug
discovery, or instead aﬀect those DISC1-binding proteins directly.
In this review, we therefore present a critical summary analysis of
the current understanding of the DISC1 protein structure by
previously undertaken biophysical studies and by bioinformatics.
We provide a comprehensive overview of DISC1 binding
regions, subcellular localization, and known sequence variants
implicated in psychiatric illness. Finally, we review in detail the
DISC1-related protein signaling pathways, which currently show
the most potential for future therapeutic intervention.
1. STRUCTURAL INFORMATION ON DISC1
Even though DISC1 was ﬁrst linked to major mental illness in
2000,2 and its importance subsequently conﬁrmed and replicated
in numerous independent genetic studies,3,4 no full-length or
even partial/fragment experimental 3-D structures have been
forthcoming. Indeed, to date, biophysical characterization of the
full-length protein is still almost totally lacking.3 In the absence of
structural information for DISC1, experimental work has relied
on shorter constructs and domain delineation based on sequence
analysis.1517 This lack of structural information leaves a serious
information gap for researchers in understanding the under-
lying eﬀects of missense mutations and single nucleotide
polymorphisms (SNPs) that have been linked to susceptibility
to disease. Are experimental results ascribed to partial con-
structs physiologically relevant or informative with respect to
a fully folded, functional DISC1? How does sequence varia-
tion in DISC1 impact on the structure and function of the
expressed protein? How do the various SNPs and mutations
contribute toward the risk of developing mental illness? Will
the structure suggest routes to the development of therapeutic
intervention?
The full-length DISC1 sequence has been suggested to consist
of two regions: (i) an N-terminal “head” domain spanning amino
acid residues ∼1350, that does not share homology to any
known fold/s, and (ii) a C-terminal coiled-coil region (spanning
∼350854) that shows greater conservation among orthologs
than the N-terminus.2,3,17,18 Via a comprehensive bioinformatics
approach, we review and reﬁne the secondary structure of DISC1.
1.1. The Case for Protein Disorder in the N-Terminal
Region of DISC1. The N-terminal region possesses only two
notable regions of conservation that correspond to a nuclear
localization signal (NLS) sequence motif18 and a serine-pheny-
lalanine-rich (SF-rich) motif.17 Another feature within the N-term-
inal region is the incidence of stretches of low-sequence complexity
and compositional bias.17 A dearth of predicted secondary struc-
ture elements is also evident.3,16 This begs the question: is the
N-terminal head domain compactly folded?
The N-terminus of DISC1 is often referred to as the globular
head domain.2,17 The term “globular” implies a folded 3-D struc-
ture in its native state. However, this region contains numerous
low-complexity segments strewn throughout its sequence as
identiﬁed by the program SEG.19 Compositional bias involving
excessive numbers of serine (consisting of 1315% of residues),
alanine, and glycine (together making up 1623% of residues)
residues was previously reported.17 Typically, low-sequence
complexity corresponds to disordered regions in proteins.20
Protein disorder refers to segments or to whole proteins that
fail to self-fold into ﬁxed 3-D structure; such disorder often exists
in its intrinsic state.20
To investigate this further, a secondary structure predictor
coupled with a series of disorder predictors via a meta-predictor
was applied to the 854 amino acid residues of full length human
DISC1 (L-isoform, SwissProt Accession Number: Q9NRI5).
These methods are capable of detecting secondary structure and
disorder from sequence information alone, with a reasonable
degree of accuracy [benchmarked ∼80% 21,22]. The human
DISC1 sequence was submitted to the disorder prediction
meta-server, MetaPrDOS (meta Protein DisOrder prediction
System),23 that utilizes seven independent predictionmethods to
produce a consensus integrated prediction (Figure 1). Use of
consensus disorder, based upon several methods, is a means of
evaluating “high-probability” disorder regions by reducing the
likelihood of an overprediction for the these regions. Consensus
disorder employs a range of computational techniques including
amino acid compositions, secondary structure prediction, and
physicochemical properties. MetaPrDOS achieved higher pre-
diction accuracy than all methods participating in the Critical
Assessment for Techniques in Protein Structure Prediction 7.23
From the derived consensus disorder prediction, using a 5%
false positive rate estimate threshold (the default setting), almost
the entire N-terminus, ∼89% (310 out of 350 residues), is
predicted to be disordered (Supporting Information Figure 1).
Even with a more stringent false positive rate (2%), a signiﬁcant
fraction (228 out of 350 residues, ∼65%) is predicted to be
disordered (Figure 1). These disordered residues occur in ﬁve
major regions of greater than 25 continuous stretches of amino
acid residues: (i) residue positions 135 (35 residues), (ii)
6795 (29 residues), (iii) 146205 (60 residues), (iv) 218260
(43 residues), and (v) 278322 (45 residues). A C-terminal
region involving residue positions 710741 was also predicted
to be disordered. This result has consequences for experiments
that require expressed protein. Extended regions of disorder
should preferably be excised or shortened when creating genetic
constructs for recombinant protein expression, puriﬁcation, and
attempts at crystallization.21 Alternative strategies can be em-
ployed, such as use of fusion protein tags that increase protein
solubility or foldability, and/or coexpression with partner pro-
teins that overlap with regions of predicted disorder. Some
regions do contain a majority of predicted consensus “order”.
For example, the regions spanning residue positions 3666,
108123, 130145, 206217, 261277, and from residue
position 333 onward the C-terminus were predicted to be
ordered. Indeed, some of these regions correspond to predicted
R-helices by PsiPred 24 (Figure 1). The ﬁrst predicted coiled-coil
region occurs only four amino acid residues beyond the R-helix
located between 326 and 342, and follows a 45 residue dis-
ordered region that contains a low-complexity stretch of serine
and glycine amino acid residues. There may thus be a case to
revise the domain boundaries of the N-terminus to 1326
(as opposed to 1350). In further support of disorder, the
PsiPred-predicted secondary structure results conﬁrm that the
N-terminus is largely devoid of conﬁdently predicted secondary
structure elements, and this region shows greater sequence
variation among orthologs17,25 than the C-terminal region (see
conservation “heat map” in Figure 2). From inference, therefore,
there is no evidence of a compact folded structure at the
N-terminus of DISC1; protein disorder is more likely.
1.2. Protein Disorder in DISC1 is Potentially Important for
Its Function. Disordered proteins can undergo a structural
transition into a folded form upon binding to a target 21 and
have several features that make them well suited to interact with
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multiple targets. These proteins are characterized by a combina-
tion of low overall hydrophobicity and high net charge. Typically,
they have significantly higher levels of certain amino acids, namely,
Glu (E), Asp (D), Lys (K), Arg (R),Gly (G),Gln (Q), Ser (S), and
Pro (P) (these constitute 60% of the N-terminal 350 amino acid
residues inDISC1), and lower levels of others, specifically, Ile (I),
Leu (L), Val (V), Trp (W), Phe (F), Tyr (Y), Cys (C), and Asn
(N) (accounting for 21% of DISC10s N-terminal 350 amino
acid residues).20,21 Disordered proteins comprise a significant
fraction of eukaryotic proteins; some estimates propose as many
as 30% of eukaryotic proteins are either completely or partially
disordered.26
Why have some proteins evolved to be disordered under
physiological conditions? Various hypotheses have been pro-
posed. A favored explanation is that the malleability of natively
disordered proteins leads to advantages with respect to regula-
tion and binding of diverse ligands. Another simple explanation
suggests that disordered proteins form very large intermolecular
interfaces within complexes.21 Both hypotheses ﬁt well with
the current scenario for multiple DISC1 interactors. Over 200
protein interaction partners have been identiﬁed by yeast two-
hybrid studies,2730 and a substantial number have been con-
ﬁrmed experimentally, as listed in the proteinprotein interac-
tion database IntAct.31 Intrinsically disordered proteins often
have some local and limited residual structure, which may be
crucial to their interactions with their binding partners, as may be
the case for the N-terminus of DISC1.
The importance of intrinsic disorder for the function of several
individual “hub” proteins (i.e., proteins with a high degree of
connectivity) has been studied in eukaryotic interactomes,32 and
its ability for transient reversible interactions reported33 [and
reviewed in refs 34 and 35]. It might be relevant that disorder
within the N-terminus of DISC1, for example, aids in its dynamic
reversible binding to cAMP-speciﬁc 30,50-cyclic phosphodiester-
ase 4B and 4D (PDE4B/PDE4D),36 the contact points of which
have been reported37 (refer to Table 1); some of these regions
correspond to predicted consensus disorder sites. An extended
surface area for the N-terminus due to protein disorder com-
bined with a potentially large surface area for the R-helical
bundle/coiled-coil C-terminal region (see below) could accom-
modate multiple proteinprotein interactions for DISC1.
1.3. Delineating the Coiled-Coil Regions within the C-Ter-
minus and Assessing DISC1 Secondary Structure. The chief
characteristic of most coiled-coils is a regular seven-residue
sequence pattern known as the heptad repeat. These are often
labeled from “abcdefg”, where positions “a” and “d” are usually
occupied by apolar residues that provide structural stability when
two ormore helices wind around each other to form “supercoils”,38
while the remaining positions are solvent exposed and usually
provide surfaces for proteinprotein interaction. These heptad
repeats are readily identified by sequence analysis and structu-
rally represent a distorted R-helix where the seven-residue repeat
forms two turns (or 3.5 residues per turn) as opposed to a regular
R-helix where 3.6 residues form one turn. Despite this apparent
simplicity and relatedness at the sequence level, coiled-coils
display a considerable degree of structural diversity; the helices
may be arranged parallel or antiparallel and may form a variety of
oligomeric states.39 The secondary structure within DISC1 was
analyzed and annotated using coiled-coil predictors along with
the secondary structure predictor, PsiPred.24
Depending onwhich program is used for detecting coiled-coils
e.g. CCHMM_PROF,40 COILS,41 MarCoil,42 Multicoil,43 Pair-
Coil2 44 and PCOILS,45 the input provided (e.g., single sequence
or multiple sequence alignment) and the stringency of the thresh-
old parameters (e.g., use of a 14, 21, or 28 residue window-size,
applying core position ‘a’ and ‘d’ residue weighting, and the
matrix employed e.g. MTK, MTIDK, PDB) the precise number
of coiled-coil regions, their extent and boundaries within DISC1,
vary.3,16,17,46 However, all the aforementioned programs predict
coiled-coil regions within the C-terminus by broad consensus
(Supporting Information Figure 2). By considering the output
Figure 1. Structural overview of DISC1. Figure depicting application of
a complementary suite of bioinformatics structure prediction methods
on the sequence of human DISC1. These results are plotted in graphical
format using an equivalent scale along the x-axis for residue position with
the conﬁdence or probability scores for each assignment along the y-axis.
(a)MetaPrDOS, the “metaserver” that provides an integrated consensus
disorder prediction (blue with dots) derived from seven independent
disorder prediction methods. The individual prediction assignment for
each method (refer to key) is also shown. (b) The PsiPred secondary
structure prediction for human DISC1 (R-helices, red; β-strands, green)
is provided. (c, d) Two independent coiled-coil method predictions
applied to DISC1 is shown; PCOILS (input, multiple sequence align-
ment from Chubb et al.;3 weight, yes; matrix, MTIDK; window, 14, 21,
28) and MarCOIL (input, human DISC1 sequence; matrix, MTIDK;
TransProb, high; window, not applicable). From this ﬁgure, the dearth
of secondary structure in the N-terminus of DISC1 is apparent. Various
segments within the N-terminus overlap with assignments of consensus
disorder tendency predictions (with a stringent false positive cutoﬀ 2%).
Also evident is the overlap between PsiPred predicted helices and the
coiled-coil helices and also the occurrence of other regular R-helices
within the C-terminus.
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from two of the better performing methods,47 at least four
regions possess coiled-coil potential by consensus (Figure 1).
These correspond to residues 347393, 452499, 603680,
and 805828. Some of these regions contain stretches of
consecutive heptad repeats (e.g., residues 462496 are predicted
to contain ﬁve consecutive heptad repeats16), while others
possess short “breaks” in their heptad repeat registers. There
also exists some ambiguity in assignment of coiled-coils. For
Figure 2. DISC1 structure schematic, sequence variants and binding sites. (a) Schematic depicting mapped secondary structure (pink, regular R-
helices; green, coiled-coil helices; light-green, ambiguous helix, maybe regular or coiled-coil) and extended consensus disorder predictions (thick yellow
lines) from Figure 1, drawn to scale. Position of sequence motifs and features are highlighted; these include the nuclear localization signal (NLS), serine-
phenylalanine-rich (SF-rich) motif, phosphorylation sites [pT50 (putative), pS54, pS713, brown triangles]14 and translocation break point t(1;11) at
amino acid position 597.1,2 Known mouse missense mutations (blue star), human common variants (black star), and human ultrarare mutations (red
star) are indicated. Ortholog sequence conservation is shown mapped below the DISC1 schematic to represent the strength of conservation for each
sequence position in DISC1 (gaps excluded); these were calculated using the program AL2CO194 using the multiple sequence alignment from Chubb
et al.,3 but excluding the fragment sequence of Bos taurus that lacked the N-terminal region to avoid bias in calculation. The AL2CO conservation score
was averaged over a 31 amino acid sliding window (15 residues either side of a central residue) and colored accordingly (refer scale for conservation
gradient). The conservation “heat map” brings out the greater variation in the N-terminus versus the C-terminus. Apparent from this depiction are the
highly conservedNLSand SF-richmotifs. Interestingly, the predicted regions of disordermap to areas of least conservation. The 13 exons that encompass full-
length DISC1 are shown above the schematic. (b) Known regions of DISC1 involved in self-association and proteinprotein interactions determined
using truncated protein constructs are shown. Green lines indicate constructs which are suﬃcient for protein binding and thus include a protein binding
domain. Where two or more overlapping constructs are each suﬃcient for interaction, the overlapping region is indicated with a solid line and the
remainder with dotted lines. Red boxes indicate regions which abolish or severely impair protein binding if deleted; these may represent protein binding
domains or other essential structural features. Yellow lightning bolts indicate small groups of 24 amino acid residues, which if mutated, abolish or
reduce protein binding. Data derived from Table 1; see references therein. All lines are drawn to scale with the DISC1 structure schematic in (a).
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example, within a predicted stretch of R-helices (between 540 and
600), the program PCOILS45 suggests that the third coiled-coil
region begins earlier at around position 540, while MarCOIL42
suggests a later start position around 603. Two leucine zipper
motifs (i.e., where leucine residues are present at position “d” of
coiled-coil heptad repeats), 458486 and 607628, are identi-
ﬁed by PROSITE,48 while a third, 808829, was suggested by
manual examination.46 The PsiPred secondary structure predic-
tion of R-helices in the C-terminus overlays appropriately with
the regions of coiled-coil helix propensity (Figure 1), but also
suggests a number of other “regular”R-helices that otherwise lack
the heptad repeat (Figure 2). Some examples include conﬁdently
assignedR-helices that occur at positions 326342, 400416, and
686708. There appear to be minor diﬀerences in agreement
between the PsiPred version used by the PCOILS server
(Figure 1) and the PsiPred server version 3.0 (http://bioinf.cs.
ucl.ac.uk/psipred/). In this case, for purposes of the schematic in
Figure 2, only the consensus regions between the two predictions
are indicated.
To summarize, by consensus the C-terminal region is pre-
dicted to be made up of at least four regions of coiled-coils that
contain identiﬁable heptad repeat registers, and at least ﬁve
“regular” R-helices that do not possess heptad repeats inter-
spersed along the sequence of DISC1. The predicted coiled-coil
segments in DISC1 are discontinuous and more dispersed than,
for example, those that occur in myosin, kinesin, or keratin that
contain continuous stretches of greater than 100 amino acids with
coiled-coil propensity. Interestingly, no β-strands are predicted
within the C-terminus. Overall, therefore, the C-terminal region
appears to possess the characteristics of a series of helical bundles
that coexist with, or partly engage in, coiled-coil interactions.
1.4. DISC1 Self-Association, Oligomeric State, and Aggre-
gation. The difficulty in expressing and purifying folded full-
length DISC1 protein has been a major stumbling block in the
DISC1 field. Previous work tapping structural aspects of the
protein has relied on truncated constructs. These however have
been limited to the C-terminus, which is unsurprising given the
disorder prediction for large swathes of the N-terminal region
of DISC1.
Brandon et al.49 noted that DISC1 formed large (g250 kDa)
species that they believed to be DISC1 dimers, or higher order
structure and quoted unpublished data that multimerization of
DISC1 could be demonstrated through interaction of FLAG- and
MYC-tagged DISC1 in HEK293 cells. A region spanning resi-
dues 403504 of DISC1 was later shown to be a functional self-
association domain by pull-down experiments with deletion
mutants expressed in HEK293 cells50 (Figure 2). This region
includes a predicted leucine zipper motif at positions 455495, a
motif that often promotes higher order oligomeric states. A
wealth of biochemical and biophysical data for several puriﬁed
C-terminal fragments was published by three recent studies.15,16,51
These C-terminal constructs included regions in DISC1 spann-
ing amino acid residues 316854, 598785, 598854, 640
854, 640854Δ22 (i.e., minus 748769), 668854Δ22 (i.e.,
minus 748769), 668854, and 765854, and the results are
summarized below.
In the ﬁrst study, Leliveld et al.15 used size exclusion chroma-
tography (SEC) to characterize multimerization of the recombi-
nant DISC1 fragment 598854. DISC1(598854) was found to
exist as dimeric, octameric, and multimeric species under phy-
siologically relevant conditions. The dimer displayed a compar-
able far ultraviolet circular dichroism (CD) spectrum as the
combined oligomer/multimer fraction, indicating that DISC1-
(598854) self-associated as folded subunits. The DISC1-
(598854) construct gradually formed aggregates (when
stored at 80 μM), suggesting a self-association continuum that
paralleled aggregation. Interestingly, the authors noted that only
the octameric state of the DISC1(598854) construct, but not
the dimers or multimers, was required for functional interaction
with nuclear distribution protein E homologue like-1 (NDEL1)
indicating that an oligomerization optimum was necessary for
interaction between the two proteins. A subsequent study using
another construct, DISC1(640854), conﬁrmed that this oligo-
meric optimum was necessary for NDEL1 interaction.16 Insight
into the size of a longer construct that encompassed all putative
coiled-coil regions, that is, DISC1(316854), was obtained by
dynamic light scattering (DLS) experiments. DISC1(316854)
had a hydrodynamic diameter (Dh) measurement of 15( 1 nm.
Additionally, a DLS reading for the DISC1(316854):NDEL1
(1:1) interaction gave aDh of 19.2( 1 nm. The authors also noted
that NDEL1 did not bind aggregates of full length DISC1 in vivo.
In the second study, using a range of other puriﬁed constructs,
Leliveld et al.16 undertook SEC and covalent cross-linking and
showed that both DISC1(668854) and DISC1(640854)
formed a mixture of dimers, one or two types of oligomer, and
soluble multimers. Although the DISC1(640854) dimer could
be isolated as a stable species, part of the oligomers immediately
dissociated to dimers after fractionation and the isolated dimers
did not associate into oligomers at the same speed. This behavior
was illustrated by DLS readings, where the DISC1(640854)
dimer had a Dh of 6.2 ( 0.8 nm and the combined oligomer/
multimer fraction had a Dh of 7.8 ( 0.4 nm, just like the non-
fractionated sample. CD spectroscopy of the DISC1(640854)
dimer fraction and the combined oligomer/multimer fraction
showed that both contained the same overall mixed alpha/beta
fold (after deconvolution of CD spectra: 32% R-helix, 18% β-
strand, 21% turnlike, 30% loop). Unlike the DISC1(598854)
construct used in the previous study,15 DISC1(640854) did
not have an aggregation threshold, rather the size distribution
shifted toward oligomers and dimers upon concentration. Size
exclusion chromatography of DISC1(765854) showed that it
only formed an ∼35 kDa species, consistent with a covalent
cross-linking experiment that showed this complex to be dimeric.
Circular dichroism spectroscopy showed DISC1(765854) to
be mainly R-helical, consistent with the presence of a predicted
coiled-coil region. SEC analysis and native polyacrylamide gel
electrophoresis of DISC1(598785) mainly showed high mo-
lecular weight multimers and small amounts of dimers and
oligomers. Its CD spectrum however was comparable to those
of both DISC1(668854) and DISC1(640854), suggesting
that overall folding in this case was not aﬀected by truncation.
Laddering of DISC1(640854) and DISC1(668854) indi-
cated regular oligomerization that was higher and less regular for
DISC1(598785), but absent for DISC1(765854). These
ﬁndings suggested that dimerization encoded within the last
coiled-coil domain (note, Leliveld et al.16 partitioned the C-term-
inal region into four coiled-coil domains) was necessary for an
orderly, concerted oligomerization together with region 668
747. SEC analysis for both DISC1(640854) and DISC1(668
854), and another construct DISC1(640854)Δ22 (minus
748769), showed that the common disease-associated C704
variant (refer to section 3) had, on average, a moderately higher
fraction of oligomers than S704. CD spectroscopy of both
variants, however, yielded exactly the same results. These results
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indicated that the fourth coiled-coil domain (765854) formed a
stable dimer and that the region between residues 668747 was
responsible for oligomerization. Although the third coiled-coil
domain was capable of aiding the formation of higher order
oligomers and multimers, it was dispensable for oligomerization
of the whole C-terminal domain. The authors concluded that the
oligomerization domain, if indeed folded like a coiled-coil domain,
was more likely to be involved in homomeric intermolecular
interactions and that the S704C variant modulated this. They
further suggested that a likely unstructured subdomain within
668774 controlledoligomerization. Indeed, this regionoverlapswith
the only extended (>25 amino acid) consensus disorder prediction in
the C-terminus that encompass residues 710741 (Figure 2).
Leliveld et al. demonstrated that detergent-insoluble DISC1
could be seen by immunoreactivity in ∼20% of post-mortem
brains of patients with chronic mental diseases, but not in healthy
controls.15 DISC1 aggregates did not bind NDEL1, whereas
insoluble DISC1(316854) aggregates did copurify with dys-
bindin, the product of another prime candidate gene associated
with mental illness,52 in brains of a subset of patients with mental
illness, but not in healthy controls.51 These ﬁndings highlight the
potential of DISC1 protein aggregation and recruitment of
binding partners as a biological mechanism in a subset of mental
illness cases,5 and while the current study only analyzed post-
mortem brain tissue, it highlights the possibility of DISC1 being a
useful biomarker in future for diagnosis, particularly if these
results were also noted in more accessible tissues.
The biophysical studies undertaken to date have provided
much needed insight into the C-terminal portion of DISC1.
However, many questions remain and some new questions arise.
Howmany quaternary states does full-length DISC1 adopt?How
many more self-association regions remain to be mapped? Do
these self-association regions act in concert in the assembly of
full-length DISC1? Or do they fulﬁll diﬀerent functions? Are
DISC1 proteinprotein interactions dependent on quaternary
state? Are the experiments that used truncated constructs physio-
logically relevant in context of the full length protein? Depending
on the conditions and the C-terminal construct examined, the
oligomeric state of DISC1 is clearly delicate16 and examples exist
where truncated constructs aﬀect the oligomerization state of
coiled-coil domains.5356
1.5. The Molecular Weights of DISC1 Species. Over 40
differentially spliced transcripts of DISC1 have been identified
from human brain tissue to date.57 It is not yet known how many
are translated, but it is clear that there aremultiple DISC1 protein
species identified by Western blotting using different antibodies
raised against DISC1 or fragments thereof. The most commonly
described molecular weights of DISC1 are around 100 kDa
(generally presumed to correspond to a protein translated from
the canonical 13 exons of theDISC1 gene,58 known as the long or
L variant; Figure 2) and one or more protein species of
approximately 75 kDa. Figure 3 displays the sizes of various
DISC1 species identified to date, with the predicted molecular
weights of proteins derived from known transcripts shown for
comparison. It should be noted that because molecular weights
displayed are as quoted by the original authors, species of similar
sizes may, in fact, represent a single species, the size of which has
been variably estimated. Conversely, multiple protein species
may share the same apparent size; for example, a 75 kDa DISC1
protein can be detected using antibodies raised against either the
N- or C-terminal regions of DISC1, implying the existence of
distinct “n-75” and “c-75” species.59
Apparent discrepancies between molecular weights of DISC1
species predicted from transcripts and those seen in vivo could
potentially be explained by multiple causes. First, post-transla-
tional modiﬁcations such as phosphorylation14 may raise the
molecular weight of the protein. Alternatively, if DISC1 forms an
elongated structure, as could occur through its putative coiled-
coil regions, then this would cause DISC1 to migrate slower
through a gel than a similarly sized globular protein would and,
therefore, show a higher apparent molecular weight. It is also
possible that some species are generated not by alternative
splicing but by post-translational cleavage of longer protein
species as hinted at by the apparent generation of both ∼100
and ∼75 kDa species by a construct exogenously expressing the
DISC1 L variant in HEK293 cells.60 The larger (130 kDa and
higher) DISC1 species can be hypothesized to arise through
DISC1 forming high binding aﬃnity protein complexes,49 either
as DISC1 oligomers or with protein binding partners, that remain
intact under standard experimental conditions.
Variation in DISC1 species detected by diﬀerent antibodies
can reasonably be expected if they are raised against epitopes
found in some but not all DISC1 variants, or are expressed in a
tissue or cell type restricted fashion. Nevertheless, the presence
of such a diverse array of protein species and variation between
antibodies,61 combined with uncertainty as to how splice variants
correspond with protein species and the lack of an established
“gold standard” antibody or DISC1 knock-down technique to aid
characterization, raises the serious possibility that some of the
apparent DISC1 species represent nonspeciﬁc antibody binding
events. This problem has been recognized but not yet resolved
and remains a priority for the ﬁeld.61 Systematic DISC1 isoform
analysis, whether by generation of exon selective and speciﬁc
antibodies or through puriﬁcation and mass spectroscopic iden-
tiﬁcation of individual DISC1 species, is required if we are to
understand this fundamental aspect of DISC1 function.
2. DISC1PROTEIN INTERACTION SITES
DISC1 acts as a protein scaﬀold, binding over 200 interactors,
many of which were originally identiﬁed in yeast two-hybrid
experiments2730 but have now been conﬁrmed in mammalian
models, for example, in cell lines or primary tissue lysate. Interest-
ingly, some of the DISC1-interactors also interact with one
another, suggesting their involvement in common pathways
(see ref 4 for a recent review). More recently, DISC1 has been
linked via convergent pathway studies to Huntington’s disease,62
suggesting a potential common biological underpinning with
respect to shared aspects of cognitive, psychotic, and mood
deﬁcits between these otherwise distinct disorders, further en-
hancing its importance as a pathﬁnder in neuropathology.
For many of these interactors, truncation mutants of DISC1
have been used to elucidate putative sites of proteinprotein
interaction. In general, these fall into two categories. First, demon-
stration of DISC1 truncates that retain protein-binding capability;
these can be assumed to contain the minimum binding site for
the interaction partner. Second, demonstration that deletion of
certain regions of DISC1 abolishes proteinprotein interaction;
these demonstrate that the region is critical for interaction.
However, it may not necessarily reﬂect a protein binding site,
but instead represent important DISC1 structural features, such
as oligomerization sites or subcellular localization signals that are
crucial for proteinprotein interaction. These experiments are
described in Table 1 and summarized schematically in Figure 2
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(refer to Supporting Information Table 1 for DISC1-interactors
that have had regions mapped by yeast two-hybrid experiments
only).
It is noteworthy thatmany of binding partners listed inTable 1,
like DISC1, also contain or are predicted to contain coiled-coil
domains. It would be interesting to ﬁnd out how many of these
proteins utilize their coiled-coil domains to facilitate DISC1-
interaction; such interactionsmay reﬂect important structural roles.
Some of the interactors in Table 1 are homologous or paralogous
proteins (e.g., the centrosomal and microtubule-organizing
proteins NDE1/NDEL1; cAMP-degrading phosphodiesterases
PDE4B and PDE4D; activating transcription factors ATF4 and
Figure 3. DISC1 transcript splice variants and protein species. The sizes of predicted DISC1 proteins from known transcripts with protein species
detected by Western blotting using anti-DISC1 antibodies are compared. First column: Black lines indicate predicted sizes of proteins encoded by each
of the splice variants described by Nakata et al.57 that were found in at least 30% of either human adult (A) or fetal (F) hippocampal samples examined.
Refer to original paper for details of exon structure for each variant. Gray lines indicate the predicted sizes of variants found in a lower proportion of
samples. Two short variants (22.2 kDa and 2.5 kDa, each found in single samples) are not shown. Remaining columns: Endogenous DISC1 protein
species detected in human (second column), primate (third column), or rodent (fourth column) by Western blotting. Dark blue lines indicate species
detected in brain tissue, and pale blue lines represent species described to date in cell lines only. Sizes indicated are as described by authors of the original
papers. Where no size was estimated, protein is not shown. Notably, Ishizuka et al. also saw several 100150 kDa species in mouse brain using a range of
antibodies,61 and Leliveld et al. detected several short (50 kDa and lower) isoforms in human brain using antibodies against the DISC1 C-terminus.15
Human Western blot data taken from refs 15, 49, 59, 64, and 114, primate data from ref 25, and rodent data from refs 8, 59, 60, 80, 140, and 195199.
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Table 1. Regions of DISC1 Important for Interaction with Its Protein-Binding Partnersa
protein assay type interacting DISC1 constructs noninteracting DISC1 constructs refs
APP OE, BL 1854 (L isoform), 1402, Lv, S, and Es isoforms 403854* 63
R-tubulin OE, BL 181357 1181, 358598, 598854 49
ATF4 OE, RP 1854 1854Δ(607628), 1854Δ(Exon9) 64
ATF5 OE 1854, 293854 1587, 697854* 27
BBS1, 4 and 8 OE 1854, 349600 1348, 601854 65
CAMDI OE, BL 446507 340400*, 533590 66
DBZ OE, CL, BL 348597, 446633 598854 67
DISC1 (self-association) OE, RP 1854, 1504, 1536, 1597, 402854 1402, 1854Δ(403504) 50
DISC1 (dimers) RP 598785, 640854, 640854Δ(748769),
668854, 765854
16
DISC1 (oligomers) RP 598785, 640854, 640854Δ(748769),
668854
765854 16
Dixdc1 OE, BL 1852, 596852 (mouse) 1220, 221355, 356595* (mouse) 68
Dysbindin OE, RP, post-mortem brain# 316854, 316854Δ(403504) 51
eIF3 p40 OE, CL, RP 1854, 1231, 1347 1115, 116231, 116347,
232347, 349854
69
FEZ1 OE 1854, 446633 1854Δ(446533) 60
Girdin& OE, RP, PN, BL 1854, 1361, 1597, 1633,
1832, 347633, 347854, 633854
1347, 361832, 598832 70, 71
Grb2 RP, BL 1854 1854(mut730/731) 72
GSK3β RP, BL 1220, 195238, 211225,
356595 (mouse)
221355, 596852, other peptides
within: 195238 (mouse)
11
Kal-7 OE, PA, PN, BL 1853, 1401, peptides:, 41100,
321355, 376410
1347, 290853, 402853,
1853Δ(350394), other peptides
73
Kendrin OE 1854, 446854 1854Δ(446533), 348597,
446533, 446633, 598854
74, 75
KIF5A OE, CL, RP, BL 1832, 1361, 1597 362832, 598832 72, 76
LIS1 OE, CL 1854, 727854 (data not shown) 1597 49, 50
MAP1A OE 1854, 1597 293854 27
MIP-T3 OE 1854, 1597, 293854 687854 27
Mitoﬁlin OE, RP, CL, PN, BL 200400, 598854, 726854 358597*, 598726 77
N-CoR OE 1854, 1854Δ(Exon9),
1854Δ(Exon911), 1854Δ(Exon13)
1854Δ(Exon913) 64
NDE1 OE, CL, BL 1854 1854Δ(802835) 78
NDEL1& OE, CL, RP, BL 1854, 1835, 293854, 598854, 727854 1357, 1597*, 1597Δ(403504),
1697*, 1726*, 1738*, 1801*,
598854Δ(807828), 697854
27, 49,
79, 80
PCM1 OE 1854, 1854Δ(802835), 1348, 601854 349600 65
PDE4B1 and 2 OE, CL, PA peptides: 3165, 101135, 196225,
266290, 611650
other peptides 36, 37
PDE4B3 OE, CL, PA 1854, 1250, 1300, 48854, 124854,
190854, 220283, 220854, 359854
1180, 284854 36, 37
PDE4D3 OE, CL, PA Peptides: 191230, 611650 other peptides 36, 37
TNIK OE, BL 1854, 1597, 1697, 1726, 1748,
1801, 1835, 46854, 150854,
245854, 291854, 302854,
313854, 324854, 335854
1854(mut 336338, 344),
348854*, 403854
81
TRIO OE, RP 1852, 1408 (mouse) 401645, 636852 (mouse) 82
aDISC1 truncation mutants, recombinant proteins, and peptides which have been tested for proteinprotein interaction beyond yeast two-hybrid
screening are listed, with outcome and corresponding references. Refer to Abbreviations for full names and aliases of proteins listed in Table 1. Assay type
abbreviations: BL = Coimmunoprecipitation in rodent brain lysate; CL = coimmunoprecipitation in cell line; OE = coimmunoprecipitation of
overexpressed protein; PA = interaction on an in vitro peptide array; PN = coimmunoprecipitation in rodent primary neurons; RP = interaction of
recombinant protein in vitro (pull down assay or copuriﬁcation); # = in a subset only, speciﬁcally with aggregated DISC1. Asterisks (/) denote constructs
which showed some interaction, but for which this was dramatically reduced compared to other DISC1 constructs. “Peptides” denote regions of DISC1
for which a variety of short peptides, spanning the listed region were tested. “Mut” denotes that mutation of the listed amino acids was suﬃcient to block
interaction. For DISC1-DISC1 interaction sites, “self-association” represents regions shown to bind in cell models, while “dimers” and “oligomers”
represent oligomeric states of the puriﬁed constructs. Where mouse constructs were used, these are mentioned. Where speciﬁc human DISC1
alternatively spliced isoforms were tested, these are indicated long (L isoform, 1854 amino acids), long variant (Lv isoform), short (S isoform), and
extremely short (Es isoform). The potential binding protein region summary is summarized schematically in Figure 2 drawn to scale with DISC1.
Ampersands (&) denote discrepancies in noted interaction domains with DISC1; these are discussed in more detail in the text.
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ATF5; Rho guanine nucleotide exchange factors Kalirin-7 and
TRIO; see Abbreviations for full deﬁnitions). These pairs or
families of proteins may thus possess equivalent binding sites with
respect to DISC1, and it would be worthwhile to tease apart
common and variable binding regions. For example, from peptide
array interaction studies of PDE4B and PDE4Dwith DISC1, it was
noted that the PDE4 family possessed both common binding sites
and also isoform-speciﬁc ones (Table 1).37
In two instances, diﬀerent groups have reported seemingly
contradictory DISC1 binding domains for the same protein. This
was the case with girdin, also known as KIAA1212.70,71 This
discrepancy can however be partially explained by the data of
Kim et al.,70 which implies the existence of two distinct girdin-
contact sites on DISC1, one in the central region (347633) and
the other at the C-terminus (633854). It can therefore be
presumed that Enomoto et al.71 detected the central binding
domain only. The onlymajor inconsistency between the two data
sets is that Enomoto et al. did not see girdin interaction with their
C-terminal construct (597854). One possible explanation for
this is that the large GST-tag on the construct of Enomoto et al.71
may have interfered with the binding process in a way that the
smaller HA-tag employed by Kim et al.70 did not. Alternatively,
the diﬀerent N-terminal cut-oﬀ points utilized may have con-
trasting eﬀects on DISC1 coiled-coil formation and therefore
alter its tertiary structure, changing its binding properties.
Two binding domains for NDEL1 on DISC1 have also been
suggested, one at the extreme C-terminus49,79 and the other
central.27 Crucially, amino acids 727854 have been shown to be
suﬃcient for NDEL1 interaction, while the binding site in the
center of DISC1 was implicated by deletion studies only. It
therefore seems more likely that NDEL1 binds DISC1 at the
C-terminus, but that some structural feature in the center of
DISC1 is important for the interaction. The most plausible
candidate would be the DISC1 self-association domain reported
by Kamiya et al.,50 given that NDEL1 interaction has been shown
by Leliveld et al.15 to be dependent on the oligomeric state
of DISC1.
Instances such as those for girdin and NDEL1 are invaluable,
as they serve to illustrate the need to carefully consider both
direct and indirect eﬀects of deletion constructs on DISC1
structure and their capacity for proteinprotein interaction.
They point also to the value of high resolution interaction
domain mapping by peptide arrays and/or site-directed muta-
genesis to test the eﬀects of speciﬁc amino acid substitutions or
post-translational modiﬁcations, including clinical mutations and
natural polymorphisms.
3. DISC1 PROTEIN SEQUENCE VARIATION: STRUC-
TURAL AND FUNCTIONAL IMPACT
Apart from the original translocationmutation,2 and a C-term-
inal frame-shift four nucleotide deletion in DISC1,83 both of
which have the potential to encode protein truncations, numer-
ous nonsynonymous common variants and ultrarare missense
mutations in DISC1 have been associated with major mental
illness. Noncoding variants in DISC1 that have also been
associated with mental illness are reviewed elsewhere.3,4 Here,
we assess the protein coding variants that have been associated
with major mental illness. We map their location and assess their
predicted consequences on structure and function with regard to
sequence conservation, location on secondary structure, and
overlap with known binding sites and other known or predicted
motifs (Table 2).
3.1. Human Common DISC1 Sequence Variants. To date,
three common amino acid variants in the DISC1 gene have been
identified as associated with psychiatric illness: R264Q, L607F,
and S704C (reviewed in refs 3 and 4).While the studies addressing
the consequences of R264Q have to our knowledge been limited
to a modest effect on cortical thickness in the lateral occipital
gyrus,94 there is a growing body of biological evidence for the
causative effects of L607F and S704C. Other common variants
have also been described, but they do not appear to be sig-
nificantly associated with schizophrenia or bipolar disorder.87,89
L607F. Carriers of the F607 allele have been shown to display
reduced gray matter in the superior frontal gyrus, anterior
cingulate cortex, and left supramarginal gyrus compared to
L607 homozygotes, as well as to suffer frommore severe positive
symptoms of schizophrenia in the case of patient carriers and
show increased dorsolateral prefrontal cortex activity during a
working memory task.94,95 The biological mechanisms under-
lying this remain to be elucidated; however, several observations
provide clues. Specifically, in cell culturemodels, the F607 variant
is associated with reduced noradrenaline release, lower levels of the
DISC1-interacting protein PCM1 (pericentriolar material 1) at the
centrosome, as well as mitochondrial trafficking defects.96,97 Cur-
iously, carriers of the F607 allele also express lower levels of a
DISC1 specific transcript whose expression is altered in schizo-
phrenia patients.57
S704C. The role of S704/C704 in brain structure has received
considerable attention, with the C704 allele being associated with
increased volumes of several brain regions.98,99 Variation of
amino acid 704 also appears to affect gray matter volume,
including parahippocampal formations,98,100,101 as well as affect-
ing white matter integrity.102 Functional imaging studies have
shown S704 homozygotes to have decreased hippocampal
activation during memory tests, greater hippocampal and para-
campal activation during memory encoding, and greater pre-
frontal cortex activation during verbal fluency tests compared to
carriers of C704.100,101,103 The C704 allele has also been
associated with higher memory test scores, lower cognitive ability
scores in elderly men, and more severe positive schizophrenia
symptoms in patients.100,104,105 At themolecular level, like L607/
F607, variation at amino acid 704 is implicated in altered
PCM1 localization and schizophrenia-related DISC1 transcript
expression.57,106 Additionally, the C704 allele is associated with
reduced activity of the kinases extracellular signal-regulated
kinase 1 (ERK1) and RAC-alpha serine/threonine-protein ki-
nase (AKT), altered binding affinities of DISC1 for NDE1 and
NDEL1, and variation in DISC1 oligomeric status.16,78,79,98
3.2. Human Ultrarare DISC1Mutations. The first large-scale
case-control mutation study of DISC1 was performed by Song
et al.87 who sequenced the coding exons and splice junctions of
DISC1 in 288 patients with schizophrenia and in 288 controls. Six
patients with schizophrenia were heterozygous for ultrarare
missense variants not found in the 288 controls (p = 0.015)
and shown to be “ultrarare” by their absence in a pool of 10 000
unrelated control alleles. They inferred that ultrarare structural
variants in DISC1 are associated with an attributed risk of 2% for
schizophrenia. In addition, they also confirmed that two of the
three aforementioned common variants (Q264R and S704C)
elevate the risk for schizophrenia slightly (odds ratio 1.3, 95%
confidence interval: 1.01.7). The five identified novel ultrarare
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Table 2. Known or Predicted Consequences of DISC1 Protein Sequence Variation on Structure and Functiona
sequence variant in DISC1
sequence conservation and
location on structure
experimental eﬀects where known and
potential binding region overlap
notes, motifs, and potential eﬀects on
structure and function
Human common variants
R264Q (Q264 minor allele
frequency 0.2599)
R in hs, pt, ma; not well
conserved, Q not seen
in any ortholog; loop
Binding region: APP,
R-tubulin, KIF5A, MAP1A,
mitoﬁlin, PCM1, TRIO
Lies close to peptide region in DISC1 266290
mapped as PDE4B1 binding. Loss or gain
of charge alters interaction propensity?
L607F (F607 minor allele
frequency 0.0986)
hs, pt, ma, bt, cf, rn, mo, tr,
dr; strictly conserved;
coiled-coil helix
Experimental: Lower levels
of the DISC1-interacting
protein PCM1 at the
centrosome for F607 (see
main text for other details of
eﬀects of L607F).
Located directly within a leucine zipper motif, within a
heptad repeat at position “d”. Change to Phe could
alter the intricate Leu-Leu packing between adjacent
helices. The presence of repeating leucine residues at
position “d” in leucine zippers is critical for modulating
coiled-coil stability, maintaining oligomeric state,
partner selection, and orientation of coiled-coil helices
as shown by numerous substitution experiments by
Harbury and co-workers on the GCN4-zipper for its
leucine positions, with other hydrophobic residues.84,85
L607F likely to impact on the structure of the protein.
Binding region: ATF4,
ATF5, Dixdc1, FEZ1,
N-CoR, PCM1.
S704C (C704 minor
allele frequency 0.2472)
hs, pt, ma, bt, rn, mo;
largely conserved
amino acid position:
G in cf, tr, dr; R-helix
Experimental: S704C alters
NDE1, NDEL1
interaction. Structurally, C704 has on
average, a moderately higher fraction of
oligomers than S704. C704S implicated
in altered PCM1 localization (see main text
for other details of eﬀects of S704C)
S704C lies close (context residue) to a predicted nuclear
export signal (NES).86 The context around the leucine
residues in the nuclear export signal that mediates
interaction has been suggested to play an important role
by la Cour et al.86 (see section 4).
Binding region: DISC1 (oligomerization),
Dixdc1, girdin, kendrin, N-CoR, PCM1.
Human ultrarare mutations seen in cases only
G14A87 hs, pt, cf; not conserved;
disordered (loop)
Binding region: APP, eIF3 p40, KIF5A,
MAP1A, PCM1, TRIO.
Lies within region that is Gly and Ala
rich (low complexity).
R37W87 hs, pt, ma, cf, rn, mo, tr, dr;
strictly conserved; R-helix
Experimental: Preliminary results suggest
W37 increases DISC1 localization
to mitochondria.88
Proximal residue in mouse Q31L mutation
(equivalent to human R35) causes
reduced binding to PDE4B1. Hence, R37W
might also aﬀect PDE4B binding, (since it
lies within binding peptide mapped to 3165).
It also lies close to Kal-7 binding site (41100).
R37W lies within tetra-arginine nuclear
localization signal motif (R35-R38).64
Binding region: APP, eIF3 p40, KIF5A,
MAP1A, PCM1, PDE4B, TRIO.
S90L87 hs, pt, cf; not conserved;
disordered (loop)
Binding region: APP, eIF3 p40, Kal-7,
KIF5A, MAP1A, PCM1, TRIO.
L90 less favorable at this position, but not well conserved.
S209R89 hs, pt, ma, cf, mo, tr, dr; very
highly conserved; R-helix
Binding region: APP, R-tubulin, eIF3
p40, KIF5A, MAP1A, mitoﬁlin, PCM1,
PDE4 (general), TRIO.
Within conserved SF-rich motif, within the PDE4 family
binding region (191230) and close to GSK3β binding
region (211225). Predicted phosphorylated site by
NetPhosK90 as a cdc2 kinase target site and also adjacent
predicted phosphorylated sites90,91 T207 and S211.
R338Q89 hs, pt, ma; Q in orthologs
rn, mo, tr, dr; R-helix
Binding region: APP, R-tubulin,
ATF5, Kal-7, KIF5A, MIP-T3,
mitoﬁlin, PCM1, TNIK, TRIO.
Wang et al.81 found that alanine substitutions for
V336, L337 and R338 together with N344 resulted
in a weakened DISC1 interaction with TNIK. R338Q
may thus be indirectly implicated as functionally
important. However, because this position is occupied
by Gln in some nonprimate orthologs, it would be useful
to undertake further mutagenesis validation using the
loss-of-charge variant. R338Q also lies within the
deﬁned Kal-7 binding region (321355).
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cohort-specific nonsynonymous variants found in cases only
were G14A, R37W, S90L, R418H, and T603I.
In a similar study, but focused on bipolar spectrum disorder,
Song et al.89 analyzed the regions of likely functional signiﬁcance
in DISC1 in 504 patients with bipolar spectrum disorder
(including a subset of cases with puerperal psychosis) and 576
ethnically similar controls. They found that ﬁve patients were
heterozygous for ultrarare protein structural variants not found in
the 576 controls (p = 0.02, one-sided Fisher’s exact test) and
shown to be ultrarare by their absence in a pool of 10 000 control
alleles. In their sample, ultrarare (private) protein structural
variants in DISC1 were associated with an estimated attributed
risk of about 0.5% for bipolar spectrum disorder. However, they
noted that the common variants were not associated with an
elevated risk of bipolar disorder. The four identiﬁed ultrarare
nonsynonymous variants found in cases only were S209R,
R338Q, R418H, and T754S. Interestingly, the R418H variant
was previously observed in their case-control study of DISC1 in
schizophrenia.
Following on from a previous linkage study on schizoaﬀective
spectrum cases107 and from an unpublished report that se-
quenced DISC1 using 14 unrelated schizoaﬀective samples from
the linkage study, two nonsynonymous coding SNPs in exon 11
were identiﬁed in two separate individuals. Green et al.92 fol-
lowed this up by sequencing exon 11 in 506 cases and in 1211
controls for variants that occurred only once. As a result, four
Table 2. Continued
Human ultrarare mutations seen in cases only
R418H87,89 hs, pt, ma, tr, dr; present
as H in cf; end of
regular R-helix
Binding region: ATF5, BBS1,
BBS4, BBS8, dysbindin, DISC1
(self-association), girdin,
GSK3β, MIP-T3.
Located within GSK3β deﬁned binding
region (356595) and near Kal-7 binding
region (376410).
T603I87 hs, pt, ma, bt, cf, rn,
mo; highly conserved
(S in tr, dr);
coiled-coil helix
Binding region: ATF5, Dixdc1,
FEZ1, N-CoR, PCM1.
Potential to disrupt phosphorylation
(predicted phosphorylation site by NetPhos91).
Also close to ATF4 binding region 606628
and near PDE4 (general) binding region
611650.
T754S89,92 hs, rn, mo; end of
regular R-helix
Binding region: Dixdc1, girdin,
kendrin, LIS1, mitoﬁlin,
N-CoR, PCM1.
Conservative substitution with variant T754S, but
position not well conserved.
P758R92 hs, pt, ma, bt, cf; loop Binding region: Dixdc1, girdin,
kendrin, LIS1, mitoﬁlin,
N-CoR, PCM1.
Structurally unfavorable change within loop.
Mouse missense mutations
Q31L8 mo, rn; Q31 is not conserved;
in humans equivalent
amino acid R35; boundary
of loop and R-helix
Experimental: Reduces PDE4 activity, but
causes an increase in GSK3 enzymatic
activity. Q31L reduces interaction with both
PDE4B and GSK3 (see main text for more
details of eﬀects of Q31L)
Part of peptide region in DISC1 3165 mapped
as important for PDE4B1 binding. However,
outside known GSK3β-binding regions. These
have however been incompletely mapped.
Clapcote et al.8 suggested likely eﬀects of the
mice mutations based upon the physicochemical
properties of amino acids; that is, glutamine is
hydrophilic and would normally be found surface
exposed. This is probably true in the case of Q31,
as it is immediately adjacent to the nuclear localization
signal.64 Q31 replaced by leucine, a hydrophobic
amino acid, would be disfavored at this position.
Binding region: APP, eIF3 p40, KIF5A,
MAP1A, PCM1, PDE4B, TRIO.
L100P8 mo, rn; L100P is not
conserved; in humans
equivalent amino acid
S100; loop
Experimental: Reduces interaction with PDE4B
and GSK3 (see main text for more details of
eﬀects of L100P).
Adjacent to the peptide region 101135 shown to
bind PDE4B. However, outside known GSK3β
binding regions. As mentioned above, these have
been incompletely mapped. However, a change from
a Leu to a Pro could have structural consequences,
since Pro is a conformationally
important amino acid.
Binding region: APP, eIF3 p40, Kal-7,
KIF5A, MAP1A, PCM1, TRIO.
aAll known DISC1 sequence variants are tabulated. The sequence conservation information was inferred on the basis of the ortholog multiple sequence
alignment shown in Chubb et al.3 hs, Homo sapiens; pt, Pan troglodytes; ma,Macaca mulatta; bt, Bos taurus; cf, Canis familiaris; rn, Rattus norvegicus; mo,
Musmusculus; tr,Takifugu rubripes; dr,Danio rerio. Predicted location on secondary structure was based upon annotationsmade usingmethods described
in Figure 1. Minor allele frequency for human common variants obtained from dbSNP93 (1000 Genome phase 1 genotype data, release 08/04/2010).
Binding region information obtained from the literature (refer to Table 1 and Figure 2).
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additional rare variants including two missense variants, T754S
and P758R, were found only in cases. Note that the T754S
variant was identiﬁed by Song et al.89 in the same individual.
Since the discovery of these ultrarare mutations is fairly recent,
there have not been any published studies thus far examining
their functional eﬀects. However, preliminary results indicate
that R37W enhances DISC1 localization to the mitochondria
and induces mitochondrial morphological abnormalities.88 By
taking into account the location and overlap of these mutations
with known binding regions and along with predicted or known
localization motifs, a few clues emerge for future experimental
follow-up (Table 2).
3.3. Mouse DISC1 Missense Mutations. N-Ethyl-N-nitro-
sourea (ENU) is a powerful mutagen that induces single base
DNA changes which can give rise to single amino acid substitu-
tions. Applied to male mice, it provides a method for inducing
and then screening for mutations in selected genes and rescuing
these by breeding. Clapcote et al. did so for mouseDISC1 exon 2
and identified and characterized two missense mutations that led
to amino acid substitutions: Q31L and L100P that were associated
with depressive and schizophrenic-like behavior, respectively.8
Mice expressing either Q31L or L100P display inhibited cortical
neuronal proliferation, aberrant neuronal migration, re-
duced dendritic spine density,108 and lower total brain
volume.8 Mechanistically, both mutations reduce the inter-
action of DISC1 with its key interacting proteins PDE4B
and GSK3.810 Furthermore, the Q31L mutant inhibits
PDE4 activity,8 and L100P affects dopamine function.109
Finally, while there is no evidence of altered enzymatic
activity for L100P, the Q31L mutation results in increased
GSK3 enzymatic activity.9,10 Neither Q31L nor L100P is
conserved between human and mouse, nor do they corre-
spond to known clinical mutations (Table 2), but as noted
their potential for structural disruption and proximity to
functional domains and protein binding regions (Figure 2
and Tables 1 and 2) does allow testable inferences to be
made as to their likely functional consequences.
4. DISC1 SUBCELLULAR LOCALIZATION
DISC1 has been shown to locate to multiple subcellular
compartments including the centrosome, at the base of cilia,
cytoskeleton, growth cones, membranes, mitochondria, nu-
cleus, and the synapse (Table 3 and references therein).
This multicompartmentalization of DISC1 within the cell
implies that it performs diﬀerent roles and may bind diﬀerent
proteins in the diﬀerent cellular components and thus
have roles in a number of cellular processes. DISC1 dysfunc-
tion, therefore, is likely to have multiple consequences for
cellular function, neural development, and ultimately mental
illness.
The dynamic mechanisms by which DISC1 locates to its
various cellular components remains to be elucidated in many
cases. In general, transport or localization of a protein to its
subcellular compartment is facilitated either by binding to a
dedicated receptor via a signal sequence, following which the
receptor shuttles the molecular “cargo” into or out of a speciﬁc
subcellular compartment, or indirectly via binding to a partner
protein. For example, DISC1 and several of its interaction
partners are transported to the growth cones via kinesin traﬃck-
ing along the microtubules,72,76 and Miyoshi et al.74 proposed
that kendrin localized DISC1 to the centrosome. Localization of
DISC1 to the ciliary base, cytoskeleton, growth cones, mem-
branes, mitochondria, and synapse may be mediated by partner
proteins (Table 3). However, we cannot rule out that there exist
localization motifs within DISC1 that are not yet deﬁned or
immediately clear-cut. By contrast, there are well-deﬁned protein
sequence motifs that confer nuclear localization and export for
DISC1 that have been subject to testing, which we review below.
Two studies have to date formed the bulk of the work
assessing nuclear localization and nuclear export signals in
DISC1.49,64 Millar et al.113 initially found that the N-terminus
of DISC1 comprising residues 1358 was important for localiza-
tion of DISC1 to the nucleus. Indeed, two putative NLS
sequence motifs were previously noticed within the N-terminal
Table 3. DISC1 Subcellular Localizationa
cellular location details and associated functions of DISC1 refs
Centrosome Involved in recruitment of kendrin, dynein, and dynactin subunits, LIS1, NDEL1, PCM1, ninein, and CAMDI to
the centrosome. Also interacts here with PDE4B, PDE4D, NDE1, and BBS4. These interactions include those
important in microtubule aster formation, neurite outgrowth, and neuronal migration.
27, 50, 65,
66, 74, 75, 79,
110, and 111
Cilia Found at the base of primary cilia and appears to regulate their formation and/or maintenance. Knockdown of
endogenous DISC1 leads to marked reduction of primary cilia. Other DISC1 interactors seen at the cilia include
the BBS family and PCM1.
112
Cytoskeleton Seen along both actin ﬁlaments and microtubules. Expression of truncated DISC1 leads to a disorganized
microtubule network.
27, 50, and 60
Growth cones Found here in the hippocampus and is involved in recruiting proteins including LIS1, NDEL1, 14-3-3ε, and
girdin via kinesin-based transport along the cytoskeleton. Also important for axonal elongation.
60, 71, 72, and 76
Membranes Found in membrane fractions where it interacts with APP, which is important in cortical precursor formation. 46, 63, and 80
Mitochondria Found at mitochondria present on microtubules and regulates their traﬃcking. Can cause mitochondria to form “ring”
structures. Interacts with mitoﬁlin within the mitochondria and is required for correct electron transport chain,
monoamine oxidase, and Ca2+ activity.
46, 59, 77, 80,
97, and 113
Nucleus Found at the chromatin, promyelocytic leukemia bodies, and outer layers of nuclear membrane. Represses ATF4
transcriptional activity and transcription of N-cadherin and alters sleep homeostasis in Drosophila.
59, 64, 114,
and 115
Synapse Seen at the postsynaptic density along with PDE4 and NDE1. Interacts with and inhibits TNIK here, leading to degradation
of key synaptic proteins. Also aﬀects dendritic spine formation through modulation of PSD-95/Kal-7/Rac1 complexes here.
8, 73, 81, 110,
and 114
aThe regions where DISC1 has been shown to localize are provided, along with summary details of known roles or associated functions therein.
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region:17,18 the classical tetra-arginine NLS motif116,117 at posi-
tion 35-RRRR-38; and a bipartite motif,117,118 that consists of
two basic residues, a ten residue spacer, and another basic region
consisting of at least three basic residues out of the next ﬁve, at
position 331-RKWEPVLRDCLLRNRRQ-347. Utilizing this in-
formation, Sawamura et al.64 conﬁrmed that DISC1 lacking the
N-terminal amino acid residues 145 did not locate to the
nucleus, while the region containing the sequence 35-RRR-
RLARRP-43 was suﬃcient to send fused-GFP to the nucleus.
Indeed, alanine substitution mutagenesis of the tetra-arginine
motif 3538 caused the mutated DISC1 to locate outside the
nucleus with enrichment at the perinuclear regions.64 They
further conﬁrmed that the bipartite NLS did not localize GFP
to the nucleus. A previous study by Brandon et al.,46 who
performed loss-of-charge substitution mutagenesis on some of
the arginine residues in the bipartite site, also did not see any
signiﬁcant eﬀect on localization, although intriguingly nor did
they report any eﬀect upon deletion of the four consecutive
arginine residues in the classical NLS motif when using a GFP-
fused DISC1 construct. Possible reasons for this discrepancy
could be due to methodological diﬀerences in the use or
attachment of the GFP tag and/or technical issues of immuno-
ﬂuorescence staining (e.g., ﬁxation, permeabilization, and/or use
of primary antibody). However, a replication mutagenesis study
would be useful to reconcile these observational diﬀerences.
Brandon et al.46 also examined the role of two potential nuclear
export signal (NES) sites in DISC1. Typically, these NES motifs
are characterized by conserved leucine-rich sequence motifs.86
However, there was no eﬀect on DISC1 localization upon
mutating the relevant leucine residues to alanines in both sites,
regions 502-CDLTPLVGQLSLGQ-515 and 619-EGLEGLLS-
KLLVLSS-633.46 While the former site between residues 502
and 515 was a likely candidate site because of the semiconserva-
tion of the leucine-rich sequence, its surrounding context, and
location within a predicted R-helix, the latter site (amino acid
residues 619633) corresponds to a predicted coiled-coil region.
In that case, the positions “a” and “d” that are occupied bymost of
the leucine residues in this motif would be buried. Sawamura
et al.64 showed that introduction of proline substitution muta-
tions in place of the leucine residues within the leucine zipper
motif spanning 607628 altered the distribution of DISC1 from
the nucleus to the cytoplasm. They additionally noted another
potential NES motif 546-LQERIKSLNL-555 (apart from the
two examined by Brandon et al.46) and showed that a serine
substitution mutation at position 553 in place of leucine leads to
distribution of DISC1(1597) from a cytoplasmic to a nuclear
localization, while this same motif tagged to GFP alone led to it
being localized entirely outside the nucleus. The authors suggest
that this was a functional eﬀect of the NES. However, caution
should be advised on this interpretation because, as for the site
examined in Brandon et al.,46 this motif is located within a
PCOILS predicted coiled-coil helix, and consequently the leu-
cine residues could be buried and inaccessible to exportin.
Hence, it is possible that the observed functional eﬀect was
caused indirectly by structural disruption. A scan for additional
potential nuclear export signals using the NetNES version 1.186
reveals three more potential NES sites at residue positions 385,
388, and 707.While positions 385 and 388 are also located within
a coiled-coil helix and potentially buried, the site at position 707
appears a likely candidate NES site. Speciﬁcally, the study by la
Cour et al.86 noted that, apart from being leucine-rich, NES
motifs in general reside in R-helices and predominate in regions
that are rich in negatively charged residues and serines. All these
characteristics are pertinent to the 707 site (686-LLGKVWEA-
DLEACRLLIQSLQLQE-709). Interestingly, the common ami-
no acid substitution polymorphism, S704C, is a context residue;
that is, the role of leucine residues that are involved in directly
binding exportin are further facilitated by other amino acids in
their vicinity that inﬂuence molecular recognition, within the
predicted NES.
5. DISC1 IN DOPAMINE AND GLUTAMATE SIGNALING
All antipsychotic drugs currently licensed for clinical treat-
ment are united by their activity at dopamine receptor D2
(DRD2), with their ability to antagonize the receptor correlating
with neuroleptic activity,119 although higher receptor occupan-
cies are known to correlate with unwanted side eﬀects.120 Results
such as these gave rise to the highly prominent dopamine theory
of schizophrenia121 which postulates that the positive symptoms
of schizophrenia arise from hyperstimulation of DRD2, while
negative and cognitive symptoms arise from hypostimulation of
DRD1 in the prefrontal cortex (PFC) (reviewed in ref 122).
More recently, genetic analysis has hinted that dopamine-
related genes such as catechol-O-methyl transferase (COMT)
may be associated with risk of schizophrenia.123 Thus the
reporting of epistatic interactions between the DISC1 gene and
COMT124 provided the ﬁrst evidence that DISC1may participate
in the therapeutically relevant dopamine pathway. Since then,
in vivo analysis of this putative intersection of pathways has been
performed. Notably, in utero suppression of DISC1 expression
by short hairpin RNA (shRNA) in mice led to a reduction of
extracellular dopamine in the PFC and apparent defects in the
maturation of axon terminals of dopaminergic projections.125
Furthermore, in a cell model, DISC1 knockdown reduced the
numbers of primary cilia expressing dopamine receptors.112
It is well established that the dopamine enhancing agents
amphetamine and methamphetamine can induce psychotic epi-
sodes similar to those in a psychotic episode of schizophrenia,122
making it interesting to note that mice with suppressed levels of
DISC1 expression aremore sensitive to methamphetamines in an
activity assay.125 The eﬀect of amphetamine is also enhanced in
otherDISC1mousemodels. Overexpressing amino acids 1597,
corresponding to the hypothetical protein truncation in the
original Scottish family,1,2 has dominant negative eﬀects in cell
models,50,80 and likewise in transgenic mice, including an en-
hanced eﬀect on locomotor activity relative to control mice.126
This may arise in part because the mutant mice display signiﬁ-
cantly reduced dopamine, and a metabolite thereof, in the frontal
cortex.126 The ENU-induced amino acid substitution L100P8
was also associated with a heightened response to amphetamines
on hyperactivity: this could be suppressed by the typical anti-
psychotic haloperidol.109 Mice expressing the DISC1(1597)
truncate also showed inhibited sensitization to methampheta-
mine when administrated in an escalating dose, designed to
represent the pattern of use of methamphetamine abusers,127
further emphasizing the potential pharmacological relevance
of DISC1.
The other prominent theory of schizophrenia concerns hy-
pofunction of glutamate signaling, derived in part from evidence
thatN-methyl-D-aspartate (NMDA) receptor antagonists lead to
symptoms reminiscent of schizophrenia.128 Based on this, clinical
trials of metabotropic glutamate receptor type 2/3 (mGluR2/3)
agonists for schizophrenia have begun with promising early
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results.129 The glutamate hypothesis is backed up by genetic
evidence implicating proteins involved in glutamatergic function,
including D-amino acid oxidase (DAAO), G72, and neuregulin 1
(NRG1) with schizophrenia (reviewed in ref 130). DISC1 was
initially linked to glutamate signaling when knockdown of DISC1
in adult-born neurons of mice was seen to lead to an increase in
spontaneous glutamatergic synaptic inputs.131 Of the glutamate
receptors, DISC1 appears to be involved in the regulation of
GluR1 function, with prolonged DISC1 knockdown leading to a
decrease in the size of dendritic spines expressing this receptor.73
DISC1, through its interaction with TNIK (TRAF2 and NCK
interacting protein kinase), also appears to modulate the degra-
dation of GluR1 by the lysosome as well as its surface expression,
with a detectable eﬀect of inhibition of the DISC1-TNIK in-
teraction on R-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) receptor currents.81
Expression of DISC1 is also regulated by glutamate signaling,
with use of NMDA receptor agonists leading to a decrease in ex-
pression of both DISC1 mRNA and synaptic DISC1 protein,132,133
and knockdown of the NMDA receptor NR1 having a similar
eﬀect.132 A direct eﬀect of NMDA signaling onDISC1 appears to
be the modulation of the synaptic complex of DISC1 with Kal-7
(kalirin-7) and PSD-95 (post-synaptic density protein 95)73which
is involved in the regulation of dendritic spine structure. Further
evidence of interaction between DISC1 and glutamate signaling
comes from the ability of DISC1 overexpression to partially
rescue overextended migration of adult born neurons caused by
NMDA receptor antagonists in mice133 and the fact that such an
antagonist had a greater eﬀect on the locomotor activity of mice
expressing DISC1(1597) both pre- and postnatally than on
mice expressing it for shorter time periods.126
DISC1 function thus intersects in a complexmanner with both
of these therapeutically relevant signaling pathways (Figure 4),
being modulated through NMDA receptor signaling and in turn
aﬀecting the surface expression of both dopaminergic and
glutamatergic receptors. Excitingly, DISC1 and its complex
may therefore provide an opening for therapeutic modulation
of either or both dopaminergic and glutamatergic receptor
function and signaling.
6. DISC1, GSK3, AND PDE4: A FUNCTIONAL COMPLEX
WITH POTENTIAL THERAPEUTIC OUTCOMES?
The interest in glycogen synthase kinase 3 (GSK3) as a DISC1
interactor was sparked by functional studies performed by Mao
et al.11 GSK3 is an enzyme strongly implicated in psychiatric
illness by virtue of its inhibition by lithium chloride, a common
mood stabilizer and primary treatment for bipolar disorder.134
Most attention thus far has focused on GSK3β, the ubiquitous
isoformwith the more severemouse knockout phenotype,135 but
two other isoenzymes also exist, both of which have been
implicated in neuronal outgrowth. GSK3R is coded for by a
separate gene, and GSK3β2 is a neuronal speciﬁc alternative
splice form of GSK3β.136 Unlike the beta knockouts, GSK3R
homozygotes are grossly normal, although brain speciﬁc deletion
does result in decreased aggression, locomotion, and fear con-
ditioning deﬁcits.135,137 This clear diﬀerence between the gross
phenotype of the mice suggests that these similar proteins
perform nonredundant roles in development, while there may
be some overlap between interacting substrates.
GSK3β is a virtually ubiquitous enzyme present throughout
hippocampal neurons, in dendritic spines, and present in both
the cytosolic and synaptosomal subcellular fractions. The en-
zyme has a large array of substrates and multiple well demon-
strated roles which include regulation of cell proliferation138
and synaptic plasticity139 with a peak in expression between
embryonic day 18 and postnatal day 10, which corresponds to the
major period of synapse formation. As DISC1 expression peaks
at E14-E15 in mice,140 a period which coincides with neurogen-
esis, a putative role for DISC1 interacting with GSK3 in cell
Figure 4. DISC1 therapeutic pathways. Neurologically relevant cellular signaling pathways inﬂuenced by DISC1 are shown. Green arrows depict
activation enzymes, or otherwise enhancement of the target functions (for example, by leading to upregulated transcription of the protein). Red arrows
depict inhibition or otherwise downregulation. Black arrows depict eﬀects which do not fall easily into one of the above categories or that are not yet fully
understood. Data on the role of DISC1 in these pathways was taken from refs 911, 36, 37, 70, 71, 98, 131, 158, and 200. Dashed arrows indicate indirect
eﬀects. Refer Abbreviations for full names and text for further details.
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proliferation was investigated. DISC1 knockdown decreases and
overexpression increases proliferation of hippocampal progeni-
tor cells both in vitro and in vivo. Furthermore, the inhibitory
eﬀect of DISC1 knockdown can be reversed by pharmacological
inhibition of GSK3. These eﬀects are mediated via β-catenin
stabilization and the Wnt signaling pathway, one of the major
targets of GSK3β.11 Indeed, DISC1 knockdown results in an
increase in the activating autophosphorylation of GSK3β, while
overexpression has the opposite eﬀect. GSK3β binds directly to
fragments 1120 and 356595 of DISC1 (Figure 2), and these
DISC1 fragments inhibit GSK3β autophosphorylation and
downstream substrate phosphorylation. A smaller peptide en-
compassing the highly conserved DISC1 residues 195238
inhibits GSK3β autophosphorylation more potently than the
commercial GSK3β peptide inhibitor L803-mts.11 Recent data
has suggested that the interaction between the two proteins may
be dependent onDISC1 phosphorylation atmouse S710/human
S713, which may lead to a developmental switch from prolifera-
tion to diﬀerentiation of neuronal precursors.14 Thus, not only
does DISC1 appear to bind GSK3β, but it also has functional
eﬀects on the activity level of the enzyme, suggesting implications
for downstream signaling of GSK3β mediated pathways.
Phosphodiesterase-4 (PDE4) enzymes are the sole means of
inactivating cAMP within the cell,141,142 allowing ﬁne spatial and
temporal control of cAMP ﬂuxes.143 The four-lettered subtypes
AD are coded for by separate genes, each of which has multiple
length splice isoforms (long, short, supershort) whose activity
can be diﬀerentially controlled.144146 In addition, the interac-
tion of DISC1 with the various isoforms of PDE4 is isoform-
dependent. Members from all four-lettered subtypes of PDE4
immunoprecipitate with 100 kDa DISC1, with PDE4C2 and
PDE4D3 (but not PDE4A5 and PDE4B1) being released under
conditions of increased cAMP.37 PDE4B did however have a
similar dynamic interaction, when bound to 71 kDaDISC136 or a
DISC1 construct lacking its N-terminal 187 amino acids.37 PDE4
inhibitors are known to show antidepressant and antipsychotic-
like like eﬀects in rodent models,147149 and also aﬀect dopami-
nergic signaling pathways in the striatum and frontal cortex by
indirectly modifying phosphorylation of synthesis related path-
ways, key receptors, and downstream signaling molecules;150,151
however, as has been previously observed,6 side eﬀects from
nonisoform-selective PDE4-inhibitors prohibit their clinical use.
Nevertheless, recent progress has been made in the identiﬁcation
of compounds with a high speciﬁcity for PDE4B,152154
PDE4D,155,156 or speciﬁc long PDE4D subtypes.155 Crucially,
allosteric PDE4D-speciﬁc inhibitors had cognitive eﬃcacy, but
with reduced emetic side eﬀects in rodents.156,157 Together,
these open the possibility that selective PDE4-inhibitors may
possess therapeutic potential.
More recent work has suggested that PDE4 activity is also
intrinsically linked to the outcome of GSK3-DISC1 interactions.
Low doses of either rolipram, to inhibit PDE4, or of Thiadiazolidine
(TDZD-8) to inhibit GSK3, have no eﬀect on the pre-pulse
inhibition (PPI) deﬁcit or the hyperlocomotion that characterizes
the L100P “schizophrenic-like”mutantmouse,9 but combined acute
treatment of DISC1 L100P with rolipram and TDZD-8 rescues
both the PPI deﬁciencies and hyperlocomotion phenotypes.10 In
the Q31L “depressive-like”mice, which have a reduction in PDE4B
activity, TDZD-8 alone improved PPI deﬁcits, decreased immobile
time in the forced swim test, and increased social motivation in a
dose dependentmanner. Bothmutations ofDISC1 lead to decreased
coimmunoprecipitation of GSK3R and β isoenzymes, suggesting
a reduced interaction of DISC1-GSK3may be responsible for the
phenotypes of these animals.10 There is as yet no evidence to
support selectivity of DISC1 binding for either isoform of GSK3.
However, genetic inactivation of GSK3R results in a rescue of the
behavioral phenotypes observed in L100P mice, and partially
rescues the histological phenotype.137 Lower inhibitory phos-
phorylation of GSK3R was also observed in the striatum of
L100P animals, while there was no change in GSK3β phosphor-
ylation or hippocampal forms of either isoenzyme.9 These
experiments suggest that deﬁcits in the ﬁne control of the
interaction between DISC1, GSK3, and PDE4 may lead to
susceptibility to psychiatric disorder, and the speciﬁc localization
of the deﬁcit may deﬁne the phenotype of the disorder. To add to
this evidence, in neuronal-type cell culture experiments, both
DISC1 overexpression and GSK3 inhibition curb the increase in
PDE4 activity in response to a forskolin-induced increase in
cAMP levels. GSK3 inhibition also tonically decreases PDE4
activity, leading to an increase in cAMP in treated SH-SY5Y
cells.158 The mechanism by which these changes occur are not
yet clear, though phosphorylation of PDE4D by GSK3β has
recently been demonstrated.159 It is important to note that
despite mounting evidence that these pathways interact func-
tionally, there is as yet no direct evidence that DISC1, PDE4, and
GSK3 all interact simultaneously within the same complex.
cAMP signaling is a further player in the outcome of interac-
tion between DISC1, GSK3, and PDE4 (Figure 4). Protein
kinase A (PKA) is an activator of PDE4 long isoforms144 and also
a substrate of GSK3β.160 Furthermore, there is also evidence that
cAMP signaling acts upstream of GSK3β.161 Forskolin increases
inhibitory phosphorylation of GSK3β, and decreases activity by
50% in primary cerebellar granule cells. These eﬀects are blocked
by administration of the PKA inhibitor H89 to cultures but are
independent of ERK and AKT signaling. Indeed, puriﬁed PKA
directly phosphorylates puriﬁed GSK3β in vitro, although im-
munoprecipitation experiments in vivo have not yet demon-
strated a direct interaction.162
The high complexity, potential for redundancy, and ubiqui-
tous nature of the signaling pathways involved in DISC1-PDE4-
GSK3 signaling makes targeting of therapeutic compounds for
these disorders diﬃcult. Despite this, there are compounds
available for use in both humans and animal models that show
some therapeutic promise. Lithium remains a frontline treatment
for bipolar disorder. There have been many behavioral studies
performed on wild type rodents to assess the eﬀects of lithium
treatment, which suggest antidepressant, anxiolytic, and antima-
nic properties.134,163 It is still unclear whether there is a deﬁnitive
molecular mechanism by which lithium exerts its eﬀects, but
pharmacological and genetic manipulation has strengthened
the case that inhibition of GSK3β is a rational therapeutic
target. GSK3β heterozygous knockout mice recapitulate the
behavioral eﬀects of lithium-treated wild types, demonstrating
decreased immobile time in the forced swim test, decreased
exploratory behavior, and decreased amphetamine induced
hyperlocomotion.134,164,165 Lithium treatment of GSK3β hetero-
zygous knockout mice results in impeded locomotion, while
GSK3β homozygous knockouts are embryonic lethal,164 suggest-
ing that there is an optimal level of GSK3β inhibition for
beneﬁcial neuroactive eﬀects. One of the key eﬀectors of lithium
treatment may be related to its eﬀect on synaptic plasticity.
Induction of long-term depression (LTD) results in an increase
in GSK3β activity in CA1 of the hippocampus. GSK3β in-
hibitors prevented the induction of LTD in in vivo recordings
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from 2 week old rat hippocampi.166 Conversely, long-term
potentiation (LTP) inhibits GSK3β activity in vivo and in vitro
through inhibitory phosphorylation,166,167 while transgenic mice
overexpressing GSK3β have signiﬁcant deﬁcits in LTP and
spatial learning deﬁcits that are rescued by lithium treatment.167
Pharmacological inhibition of GSK3 by speciﬁc inhibitors
produces very similar eﬀects in mice to those exhibited in
response to lithium treatment. Thiadiazolidine has anxiolytic
and antimanic properties.134,168 In mice with the dopamine
active transporter knocked out, lithium antagonizes dopamine
dependent hyperactivity, as do the speciﬁc GSK3 inhibitors
SB216763, sodium valproate, and TDZD-8.165 GSK3 speciﬁc
inhibition in wild type mice also leads to decreased immobile
time in the forced swim test,137,168 one of the best replicated
eﬀects of lithium treatment.163
In cell culture and post-mortem studies, treatment with
antipsychotic drugs also has eﬀects on GSK3β activation. Short-
term treatment of SH-SY5Y cells with clozapine results in
increased inhibitory phosphorylation of GSK3β and an accumu-
lation of β-catenin in the nucleus.169 Acute risperidone, olanza-
pine, and clozapine treatment increases inhibitory GSK3β
phosphorylation in multiple brain regions of relevance to psy-
chiatric disorders. Interestingly, lower doses of risperidone have a
greater eﬀect on GSK3β phosphorylation than high doses. In the
same paradigm, haloperidol has no eﬀect.170 The evidence for
GSK3β playing an important role in multiple psychiatric dis-
orders is multileveled and growing rapidly and is strengthened by
its association with DISC1 and PDE4.
6.1. DISC1-GSK3-PDE4 and Neurotrophin Signaling. Sig-
naling cascades crucial for the regulation of synaptic plasticity,
formation of dendritic spines, neuronal complexity, differentiation,
and survival by activation in response to neurotrophins171175 also
interact with the DISC1-GSK3-PDE4 complex at multiple levels.
Brain-derived neurotrophic factor (BDNF) is a molecule of
particular interest in depression176,177 and when administered
centrally has antidepressant effects in multiple behavioral tests.178
Chronic administration of antidepressants increases BDNF
mRNA in the hippocampus.176 Treatment of SH-SY5Y cells
with BDNF leads to a decrease in GSK3β activity via AKT
mediated inhibitory phosphorylation and results in increased
phosphorylation of the cAMP response element binding protein
(CREB), as does treatment of cells with lithium.179,180 Over-
expression of GSK3β blocks BDNF induced phosphorylation of
CREB, except in the presence of lithium, which also causes a
small increase in ERK1/2 and CREB phosphorylation in control
(non-BDNF treated) cells.173
CREB is one of the major downstream eﬀectors of neurotro-
phins and has similar antidepressant eﬀects to BDNF when
expressed in the hippocampus.181 CREB is activated by chronic
antidepressant treatment,182 ERK (via ribosomal S6 kinase), and
PKA by phosphorylation173,183,184 and negatively regulated by
GSK3β.180 ERK and AKT signaling is activated by phosphoryla-
tion after chronic treatment with valproate, and short-term
treatment with carbamazepine enhances basal and BDNF stimu-
lated ERK1/2 and CREB phosphorylation.171,173 Both of these
drugs are commonly used mood stabilizers. Phosphorylation of
AKT in response to valproate treatment is accompanied by an
increase in inhibitory phosphorylation of GSK3β, while lithium
treatment has this same eﬀect without an increase in AKT
phosphorylation.185 This information leads to a central pathway
inextricably linked to psychiatric disorder, by its outcomes
(control of neuronal plasticity and survival), by its modulation
at various points by antidepressant and mood stabilizing drugs,
and by post-mortem evidence from human disease. Schizophre-
nic patients have 68% decreased levels of AKT protein in
peripheral tissues and decreased levels in post-mortem frontal
cortex and hippocampus when compared to a control popula-
tion. There are concomitant decreases in inhibitory phosphor-
ylation of GSK3β in the periphery and brain post-mortem
tissue.186
To summarize, growth factors, particularly BDNF, bind to
tyrosine kinase receptors and activate phosphoinositide-3-kinase
(PI3K) and mitogen activated protein kinase (MAPK) cascades,
resulting in phosphorylation of ERK1/2 and AKT (Figure 4).
Activation of ERK leads to activating phosphorylation of CREB,
which binds to CRE response elements in multiple genes,
resulting in transcription of neuronal plasticity and survival
related genes. Concomitant activation of AKT results in inhibi-
tion of GSK3β, allowing CREB activation. This basic pathway
can be stimulated by mood stabilizing and antidepressant drugs,
by either direct inhibition of GSK3β or upstream activation of
ERK and AKT.183 This pathway therefore has three major
outcomes with implications for psychiatric disease: activity
changes downstream of ERK such as CREB mediated gene
transcription, activity changes downstream of AKT, including
activation of mammalian target of rapamycin (mTOR) which
phosphorylates eukaryotic translation initiation factor 4E (eIF-
4E) binding protein to regulate translation,163,187 and changes in
DISC1 associated GSK3 and PDE4 activity. As an example of the
latter, GSK3β inhibits the accumulation of β-catenin through
phosphorylation leading to ubiquitination,134 while DISC1 has
been proven to stabilize β-catenin through an inhibitory eﬀect on
GSK3β.11 β-catenin is implicated in Wnt independent dendritic
morphogenesis188 and synaptic plasticity,189 and this may go
some way to explaining the changes in synaptic complexity seen
in DISC1 mutant mice.
6.2. DISC1: Effects onAKT Signaling Independent of GSK3.
DISC1 is capable of modulating these pathways by means likely
independent of its direct association with GSK3. Small interfer-
ing RNA (siRNA) knockdown of DISC1 in primary cortical
cultures results in significantly decreased phosphorylation of
ERK1/2 (pERK) and AKT (pAKT).98 Viral transduction of
both the S704 and C704 variants of DISC1 results in an increase
in pERK1/2 and pAKT. These effects are more significant when
the Ser variant is overexpressed: the pAKT increase after over-
expression of the Cys variant is nonsignificant.98 In rescue
experiments, overexpression of Ser DISC1 variant compensated
for the decrease in pERK1/2 resulting from siRNA mediated
DISC1 knockdown. There was a nonsignificant return to basal
pERK1/2 levels when the Cys variant was overexpressed: a
similar pattern was observed with pAKT.98 Thus, it seems that
DISC1 plays a similar biological role to that of mood stabilizers in
this paradigm and is capable of enhancing ERK and AKT
activation, with the potential to exert effects on synaptic plasticity
and neuron survival as described earlier.
In addition, DISC1 forms a ternary complex with kinesin-1
and Grb2, an adapter molecule linking neurotrophin binding at
tyrosine kinase receptors to downstream eﬀectors such as Ras by
recruiting guanine-nucleotide exchange factors.72 Ras acts up-
stream of AKT and ERK in the MAPK and PI3K signaling
pathways.190 DISC1 and Grb2 are partially colocalized along
microtubules in the central region of primary rat hippocampal
axon growth cones: DISC1 knockdown prevents Grb2 from ac-
cumulating in this area. Growth cone localization of Grb2 is
625 dx.doi.org/10.1021/cn200062k |ACS Chem. Neurosci. 2011, 2, 609–632
ACS Chemical Neuroscience REVIEW
rescued by overexpression of wild type DISC1, but not by over-
expression of DISC1 with a mutated SH3 binding domain.72
However, unlike the observations described above in unstimu-
lated neurons, knockdown of DISC1 has no eﬀect on ERK2
phosphorylation in neurotrophin-3 (NT-3) treated PC12 cells.
UnderNT-3 stimulated conditions, DISC1 knockdown results in
an axon elongation defect which is not rescued by overexpression
of the SH3 domain mutated DISC1.72 Conversely, the axon
elongation defect seen in non-NT-3 stimulated neurons is
rescued by both wild type and mutated DISC1, suggesting that
the DISC1/Grb2 interaction is only critical for NT-3 stimulated
axon elongation.72 These studies suggest a possible pathway by
which DISC1 may alter ERK and AKT phosphorylation, but
there are some discrepancies between the two pieces of work
which have yet to be resolved. It may be that the diﬀerences
between the eﬀects of DISC1 observed in unstimulated neurons
arise from methodological diﬀerences (such as diﬀerences in
cortical versus hippocampal neurons), or the situation may be
more complex than is presently appreciated.
Knockdown of DISC1 in the adult mouse brain results in a
cellular phenotype very similar to that of phosphatase and tensin
homologue (PTEN) suppressed mice.191 Adult born neurons in
the dentate gyrus microinjected with aDISC1 shRNA-containing
oncoretrovirus have larger cell bodies, an increased number of
ectopic primary dendrites, more complex dendritic arborization,
and an accelerated rate of synapse formation and may over-
migrate through cortical layers.131 In the PTEN mutant mice,
cells with ectopic dendrites exhibit an increase in pAKT and
phosphorylated GSK3β, whereas cells without ectopic dendrites
have no pAKT changes.191 This phenotypic similarity led to the
hypothesis that DISC1 regulates the development of adult born
neurons through activation of AKT signaling. Although there is
no direct binding between DISC1 and AKT,70 multiple lines of
evidence suggest a functional interaction. DISC1 directly binds
girdin, a protein which is expressed during diﬀerentiation of adult
born neurons, and binds to AKT to potentiate AKT activation.192
There are important points of diﬀerence between the experi-
mental approaches taken and the conclusions drawn, including
the domains of DISC1girdin interaction and of the down-
stream eﬀects on AKT signaling that remain to be resolved, but
the potential implications for DISC1 modulation of AKT signal-
ing via girdin are provocative193 and merit follow up. Thus,
DISC1 single cell knockdown resulted in an increased immu-
nostaining of pAKT in immature post-mitotic neurons; over-
expression of girdin was suﬃcient to elevate levels of pAKT and
pS6 without insulin stimulation, but this was antagonized by
coexpression of DISC1; while overexpression of DISC1 alone
had no eﬀect on pAKT levels in either insulin stimulated or
unstimulated cells.70 This is in contrast to earlier observations in
cortical neurons, where DISC1 overexpression in unstimulated
cells resulted in an increase in pAKT.98 Girdin overexpressing
neurons (thus increasing AKT signaling) exhibit a cellular
morphology and dendritic arborization strikingly similar to
PTEN and DISC1 knockdown neurons, as do neurons expres-
sing a constitutively active form of AKT. Both these neuron types
exhibit a migration and integration phenotype, but less severe
than is observed with DISC1 knockdown.70 Rapamycin can be
used to inhibit mTOR, a kinase enzyme that functions down-
stream of AKT. mTOR regulates translation by phosphorylating
eIF-4E. Rapamycin application fully rescued the eﬀects of DISC1
knockdown or girdin overexpression in adult born neurons, while
having no eﬀect on S6 phosphorylation or morphology in control
cells. Application of SB216763, a speciﬁc inhibitor of GSK3β,
had no signiﬁcant rescue eﬀect, implicating mTOR as the path-
way of interest with respect to diﬀerentiation, growth, and
integration of adult born neurons.70
7. FUTURE DIRECTIONS AND CONCLUDING REMARKS
To conclude, in the ﬁrst 10 years of research beyond the
discovery of DISC1, much has been learned about the genetics
and biology of this intriguing and novel scaﬀold protein. DISC1
clearly plays a fundamental role on neurodevelopment and neuro-
signaling, processes which are abrogated to greater or lesser
extent by clinical and experimental mutations in both human
subjects and laboratory animals. In some, but not all, examples, it
is already possible to draw direct, if partial, conclusions about the
pathogenic mechanisms of sequence variants and, through
bioinformatics analyses, make useful experimental predictions.
The multiple interacting protein partners of DISC1 identify
pathways and potential targets of relevance to schizophrenia,
bipolar disorder, and potentially more generally for cognition
and depression. The recent evidence highlighting both cAMP
and Wnt signaling, the potential impact on AKT signaling, and
the accumulating evidence for a role in both dopaminergic and
glutamatergic signaling put the DISC1 pathway ﬁrmly on the
table as a promising target for rational drug development. But this
is just the start of a much longer and challenging process.
Without a fuller knowledge and understanding of the biophysical
and structural properties of native andmutant DISC1, on its own
and bound to physiologically relevant protein partners, there will
be strict limits to what can be inferred or deduced with regards to
the structurefunction relationships necessary for a more complete
understanding of DISC1 biology, and the scope for therapeutic
intervention.
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